CN112225791A - Sericin peptide and application thereof - Google Patents
Sericin peptide and application thereof Download PDFInfo
- Publication number
- CN112225791A CN112225791A CN202011210789.5A CN202011210789A CN112225791A CN 112225791 A CN112225791 A CN 112225791A CN 202011210789 A CN202011210789 A CN 202011210789A CN 112225791 A CN112225791 A CN 112225791A
- Authority
- CN
- China
- Prior art keywords
- sericin
- inflammatory
- peptide
- application
- sericin peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010013296 Sericins Proteins 0.000 title claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 33
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 2
- 230000028709 inflammatory response Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 11
- 229920001184 polypeptide Polymers 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002542 parent ion scan Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a sericin peptide and application thereof, wherein the amino acid sequence of the sericin peptide is shown in SEQ ID NO.1, and the polypeptide can be prepared by pretreating cocoon sheets and then extracting with water to obtain sericin and hydrolyzing the sericin, or can be artificially synthesized; the obtained sericin has an effect of inhibiting inflammatory factors, and thus can be used for preparing an anti-inflammatory agent.
Description
Technical Field
The invention relates to the field of biomedicine, in particular to a sericin peptide and application thereof.
Background
Sericin is originally a waste material of the reeling industry, and its application has been receiving attention in recent years. Firstly, the safety of sericin has been approved by a series of researches, which has a precondition for application in tissue engineering materials and daily chemical skin care. Secondly, the antioxidant, whitening and moisturizing effects of the composition are widely applied. Sericin is an effective ingredient in the cosmetic raw material list, but sericin-1 protein has a molecular weight of about 400 k. As a macromolecular protein, sericin is generally hydrolyzed in use. However, neither macromolecular sericin nor hydrolyzed sericin has reported the function of sericin against inflammatory factors induced by LPS. In addition, the excavation of the effective small molecular polypeptide in the sericin is beneficial to deeper application of the sericin.
LPS is a marker structure on the cell wall of gram-negative bacteria, and the inhibition of inflammatory response caused by LPS means that the inflammatory response generated by the action of bacteria and sterilized bacterial fragments on human bodies can be inhibited. In vitro experiments, RAW264.7 cells were stimulated with LPS, which was converted from an aggregated form to a lipopolysaccharide binding protein (LPB), then to a monomeric form and transferred to CD14 in an albumin-dependent manner. Next, LPS is transferred to the TLR4/MD2 complex to form a TLR4/MD 2/LPS activity complex, which signals and activates a series of inflammatory responses. Using this model, it is possible to assess whether the efficacy agent has anti-inflammatory activity.
Disclosure of Invention
In view of the above, an object of the present invention is to provide a sericin peptide; the invention also aims to provide application of the sericin peptide.
In order to achieve the purpose, the invention provides the following technical scheme:
1. a sericin peptide, wherein the amino acid sequence of the sericin peptide is shown as SEQ ID No. 1.
2. The application of the sericin peptide in preparing an anti-inflammatory preparation.
In the invention, the sericin peptide is applied to the preparation of a preparation for reducing the content of inflammatory factors in inflammatory reaction.
In the present invention, the inflammatory factors are IL-1. beta. and IL 6.
In the present invention, the inflammatory response is an inflammatory response induced by LPS.
The invention has the beneficial effects that: the invention discloses a sericin peptide and application thereof, wherein extracted sericin is hydrolyzed, and polypeptide possibly having anti-inflammatory effect is screened from more than two thousand pieces of polypeptide information, and in vitro experiments show that the obtained polypeptide has the effect of inhibiting inflammatory factors and is a main anti-inflammatory effect substance in sericin.
Drawings
In order to make the object, technical scheme and beneficial effect of the invention more clear, the invention provides the following drawings for explanation:
FIG. 1 shows the results of ELISA assay for inflammatory factors.
FIG. 2 shows the results of real-time quantitative PCR detection of inflammatory factors.
Figure 3 is a graph of the anti-inflammatory effect of sericin.
Detailed Description
The present invention is further described with reference to the following drawings and specific examples so that those skilled in the art can better understand the present invention and can practice the present invention, but the examples are not intended to limit the present invention.
Example 1 extraction of sericin
The extraction method of sericin comprises the following steps:
(1) cleaning the silkworm cocoons with water;
(2) cutting into 2x 2cm pieces, and treating at 120 deg.C in oven for 2.5 hr;
(3) adding Milli-Q water according to a bath ratio of 1:30, and treating at 120 deg.C for 1h and 2h respectively;
(4) filtering cocoon sheet residues, and collecting a protein extracting solution;
(5) freeze drying the protein extractive solution to obtain powder, and storing in refrigerator at-20 deg.C.
The sericin obtained by the high-temperature treatment for 1h is numbered as HS1, and the sericin obtained by the high-temperature treatment for 2h is numbered as HS 2.
Example 2 anti-inflammatory Effect of sericin
1. The cell culture method comprises the following steps:
culturing the cells at 37 deg.C with 5% CO2The NIH3T3 and HaCaT cell lines were cultured in DMEM medium containing 10% fetal calf serum, and the RAW264.7 cell lines were cultured in 1640s medium containing 10% fetal calf serum. All cell lines were fluid changed daily and passaged every other day.
Three cells were treated with HS1 and HS2 prepared in example 1 while using three commercially available sericins (nos. S1, S2, S3) as controls, and then inflammatory factors were detected by real-time quantitative PCR and ELISA.
2. ELISA detection
(1) After the cells are treated, sucking cell culture fluid, centrifuging at 13500rpm for 10min, and taking supernatant; used or stored at-20 deg.C for use.
(2) Adding 100 microliter of cell culture sample, standard substance and contrast into a micropore, and repeating 3 samples; sealed and incubated for 2h at room temperature.
(3) The sample was removed and the wash repeated 3 times with wash buffer.
(4) Add 200. mu.L of detection antibody to each well, seal, and incubate at room temperature for 2 h.
(5) And (4) repeating the operation of the step (3).
(6) 200uL of HRP-labeled secondary antibody was added to each well and incubated at room temperature in the dark for 20 min.
(7) And (4) avoiding light, and repeating the operation of the step (3).
(8) Adding 100 mu L of TMB substrate, sealing, and incubating at room temperature for 20-30 min.
(9) Add 50. mu.L STOP solution and shake gently.
(10) Absorbance at 450nm was measured within 30min after the addition of the STOP solution, and the results are shown in FIG. 1.
3. Fluorescent quantitative PCR detection
The experiment comprises three parts of RNA extraction, reverse transcription and fluorescence quantitative PCR. The method comprises the following specific steps:
RNA extraction:
(1) the cells were treated and washed twice with PBS after the treatment.
(2) Every 10 th6The cells were lysed by adding 1mL TRIZOL, gently pipetting, mixing well, and then centrifuging at 12000rpm for 10 min.
(3) 200uL of chloroform was added to each 1ml of the TRIZOL reagent lysed samples and incubated at room temperature for 20 min.
(4) Centrifuge at 12000rpm for 15min at 4 ℃. The upper aqueous phase was transferred to a clean rnase-free centrifuge tube.
(5) Adding isopropanol with equal volume, mixing, and incubating for 10 min; centrifuge at 12000rpm for 10min at 4 ℃.
(6) The supernatant was removed, 1mL of 75% ethanol was added to each 1mL of TRIZOL lysed sample, mixed well, and centrifuged at 7000rpm for 5min at 4 ℃. Repeating for 1-2 times.
(7) Carefully removing the ethanol solution by suction, and drying at room temperature for 5-10 min.
(8) Adding about 40uL of RNase-free water, repeatedly beating to dissolve RNA completely, and storing the obtained RNA solution at-80 ℃ for later use.
Reverse transcription:
(1) the purity and concentration of RNA was determined using Nano-drop.
(2) The DNA in the system was removed as shown in Table 1:
TABLE 1 DNA removal System
Digesting in metal bath at 42 deg.C for 2 min.
(3) 10uL 2x super RT Mix (containing gDNA digesterter inhibitor) was added.
(4) Reverse transcription was performed in a PCR instrument under the conditions shown in Table 2:
TABLE 2 reverse transcription conditions
A fluorescent quantitative PCR method:
(1) the quantitative primers are shown in Table 3.
TABLE 3 quantitative PCR primers
(2) The reagents are shown in Table 4:
TABLE 4 fluorescent quantitative PCR reaction System
The PCR reaction process is shown in Table 5:
TABLE 5 PCR reaction procedure
The results of the detection are shown in FIG. 2. The results show that both HS1 and HS2 prepared in example 1 have the ability to resist LPS-induced inflammatory factors and are not significantly different. And the anti-inflammatory abilities of S1, S2 and S3 are different.
By comparing the results of real-time quantitative PCR and inflammatory factor ELISA, the results show that sericin can reduce the inflammatory reaction of RAW264.7 cells to a certain extent: s1, S3, HS1, HS2 showed the ability to inhibit IL-6 and IL-1 β production (jp <0.05,/pp <0.01,/pp < 0.001). S1 slightly inhibited TNF-. alpha.synthesis at the protein level, S3 slightly inhibited TNF-. alpha.synthesis at the mRNA and protein levels, but showed no significant difference (P > 0.05). HS1 and HS2 showed the ability to inhibit TNF-alpha synthesis at both mRNA level (P <0.05) and protein level (P < 0.01). S2 increased IL-6 and IL-1 β synthesis at the mRNA and protein levels (# P <0.05, # P <0.01), and also slightly increased TNF- α synthesis (P > 0.05). Overall, only HS1 and HS2 inhibited the production of three inflammatory factors. The sericin extracted by the method has the effect of inhibiting inflammatory factors, but other brands of sericin do not have the effect.
Example 3 sericin hydrolysis and anti-inflammatory Effect
In order to understand the function of the polypeptide after sericin hydrolysis, the sericin hydrolysis is subjected to LC-MS/MS detection, and the LC-MS/MS detection method comprises the following steps:
adopting an FASP enzymolysis method, and performing the process according to enzymolysis-desalination-mass spectrometry-protein identification, wherein the method comprises the following specific steps:
enzymolysis:
(1) adding 100mM DTT into protein solution, heating at 95-100 deg.C for 5min, and cooling to room temperature.
(2) Add 200. mu.L of UA buffer and mix well. Transferring into a 30kD ultrafiltration centrifugal tube, centrifuging for 15min at 14000g, and discarding the filtrate.
(3) And (4) repeating the step (2).
(4) 100 μ L of 100mM IAA buffer was added and shaken at 600rpm for 1 min.
(5) The reaction mixture was left at room temperature in the dark for 30min, and centrifuged at 14000g for 15 min.
(6) Add 100. mu.L UA buffer and centrifuge at 14000g for 15 min.
(7) Repeating step (6) twice to remove DTT and IAA.
(8) Add 100. mu.L of 25mM NH4HCO3Solution, 14000g centrifuged for 15min
(9) Repeating the step (8) twice to remove UA.
(10) Adding 40 μ L of Trypsin, oscillating at 600rpm for 1min, sealing, and performing enzymolysis at 37 deg.C for 16-18 h.
(11) Changing new collecting tube, centrifuging at 14000g for 15min, adding 4, 40 μ L of 25mM NH4HCO314000g, centrifuging for 15min and collecting the filtrate.
Desalting:
(1) desalting the peptide fragment with a C18 Cartridge column.
(2) After the peptide fragment is freeze-dried, 40 mu L of 0.1% formic acid solution is added for redissolving and quantification.
Mass spectrometry analysis:
(1) according to the quantitative results, 3uL of the enzymatic product was analyzed by LC-MS/MS according to the following settings.
(2) Separation was performed using HPLC liquid phase system Easy nLC.
The buffer solution A is 0.1% formic acid aqueous solution, and the solution B is 0.1% formic acid acetonitrile aqueous solution (acetonitrile is 84%); the column was equilibrated with 95% of solution A.
(3) A chromatographic column: thermo scientific EASY column (2cm 100 μm 5 μm-C18);
and (3) analyzing the column: thermo scientific EASY column (75 μm 100mm 3 μm-C18);
flow rate: 300 nL/min.
The relevant liquid phase gradients are shown in table 6:
TABLE 6 liquid phase gradient
(1) The peptide fragments were chromatographically separated and analyzed by mass spectrometry. The relevant parameters are as follows:
mass spectrometry: q-active (thermo scientific);
analysis duration: 120 min;
the detection mode is as follows: a positive ion;
parent ion scan range: 300-1800 m/z;
first-order mass spectrum resolution: 70,000at m/z 200;
AGC target:3e6;
first order Maximum IT: 50 ms;
the mass-to-charge ratio of the polypeptide and fragments of the polypeptide was collected as follows: 20 fragment patterns (MS2 scan) were acquired after each full scan;
second-order mass spectrum resolution: 17,500at m/z 200, Microscan: 1, Isolation window:2 m/z;
secondary Maximum IT: 60 ms;
MS2 Activation Type:HCD;
Normalized collision energy:27eV;
Dynamic exclusion:60.0s,Underfillratio:0.1%。
protein identification:
(2) the original files were database-searched by using Mascot database-search analysis software.
The database searching is set as follows:
Enzyme:Trypsin;
missed cleavage sites;2;
fixing and modifying: carbammidomethyl (C);
dynamic modification: oxidation (M) and Acetyl (Protein N-term);
screening criteria for database search peptides: mascot score >20 points.
Sericin peptide was selected by molecular docking and kinetic methods, predicted by sybyl-x2.1.1 software, with the sequence:
sericin peptide: VEQSQDKSKY (SEQ ID NO. 1);
then, the polypeptide shown in SEQ ID NO.1 is artificially synthesized, and then the synthesized polypeptide is experimentally verified, wherein the experimental method adopts the method of example 2, and the result is shown in FIG. 3. The results showed that macrophage RAW264.7, after LPS treatment, produced inflammatory factors IL-1 β and IL6(Blank samples), whereas samples pretreated with Sericin Peptide produced greatly reduced inflammatory factors (Peptide samples) and were more effective than the Sericin control (Sericin samples). The positive control polymyxin B also reduced the production of inflammatory factors (PB samples). The results show that the sericin peptide has the effect of inhibiting inflammatory factors and is the main anti-inflammatory effect in the sericin.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Sequence listing
<110> university of southwest
<120> sericin peptide and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Val Glu Gln Ser Gln Asp Lys Ser Lys Tyr
1 5 10
Claims (5)
1. A sericin peptide which is characterized in that: the amino acid sequence of the sericin peptide is shown as SEQ ID NO. 1.
2. Use of the sericin peptide as defined in claim 1 for preparing an anti-inflammatory agent.
3. Use according to claim 2, characterized in that: the application of the sericin peptide in preparing a preparation for reducing the content of inflammatory factors in inflammatory reaction.
4. Use according to claim 3, characterized in that: the inflammatory factors are IL-1 beta and IL 6.
5. Use according to claim 2, characterized in that: the inflammatory response is an inflammatory response elicited by LPS.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011210789.5A CN112225791B (en) | 2020-11-03 | 2020-11-03 | Sericin peptide and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011210789.5A CN112225791B (en) | 2020-11-03 | 2020-11-03 | Sericin peptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112225791A true CN112225791A (en) | 2021-01-15 |
CN112225791B CN112225791B (en) | 2021-10-22 |
Family
ID=74122746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011210789.5A Active CN112225791B (en) | 2020-11-03 | 2020-11-03 | Sericin peptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112225791B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898398A (en) * | 2021-02-04 | 2021-06-04 | 西南大学 | Truncated protein of silkworm egg collagen and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10245345A (en) * | 1997-03-03 | 1998-09-14 | Seiren Co Ltd | Agent for preventing dermatitis |
US7157273B2 (en) * | 2001-04-17 | 2007-01-02 | Seiren Kabushiki Kaisha | Medium additives and media for culturing animal cells |
CN105331661A (en) * | 2015-11-24 | 2016-02-17 | 浙江汇能生物股份有限公司 | Method for preparing sericin polypeptides with aqueous enzymatic method |
CN106729742A (en) * | 2017-04-01 | 2017-05-31 | 中山大学 | A kind of cancer target sericin micella and its preparation method and application |
CN107118266A (en) * | 2017-04-13 | 2017-09-01 | 上海交通大学 | A kind of sericin peptide taken and its preparation and application with α glucoside inhibiting activities |
CN108409848A (en) * | 2018-03-07 | 2018-08-17 | 西南大学 | The preparation method and applications of sericin polypeptide |
CN108451779A (en) * | 2018-05-29 | 2018-08-28 | 苏州蔻美新材料有限公司 | A kind of anti-inflammatory essence microcapsules and preparation method thereof |
CN110639007A (en) * | 2019-11-19 | 2020-01-03 | 西南大学 | Oral recombinant human lactoferrin silk protein hydrogel and application thereof in preparation of immunity enhancing drugs |
-
2020
- 2020-11-03 CN CN202011210789.5A patent/CN112225791B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10245345A (en) * | 1997-03-03 | 1998-09-14 | Seiren Co Ltd | Agent for preventing dermatitis |
US7157273B2 (en) * | 2001-04-17 | 2007-01-02 | Seiren Kabushiki Kaisha | Medium additives and media for culturing animal cells |
CN105331661A (en) * | 2015-11-24 | 2016-02-17 | 浙江汇能生物股份有限公司 | Method for preparing sericin polypeptides with aqueous enzymatic method |
CN106729742A (en) * | 2017-04-01 | 2017-05-31 | 中山大学 | A kind of cancer target sericin micella and its preparation method and application |
CN107118266A (en) * | 2017-04-13 | 2017-09-01 | 上海交通大学 | A kind of sericin peptide taken and its preparation and application with α glucoside inhibiting activities |
CN108409848A (en) * | 2018-03-07 | 2018-08-17 | 西南大学 | The preparation method and applications of sericin polypeptide |
CN108451779A (en) * | 2018-05-29 | 2018-08-28 | 苏州蔻美新材料有限公司 | A kind of anti-inflammatory essence microcapsules and preparation method thereof |
CN110639007A (en) * | 2019-11-19 | 2020-01-03 | 西南大学 | Oral recombinant human lactoferrin silk protein hydrogel and application thereof in preparation of immunity enhancing drugs |
Non-Patent Citations (4)
Title |
---|
PORNANONG ARAMWIT 等: ""Anti-inflammatory potential of silk sericin"", 《NAT PROD COMMUN》 * |
TAKAHASHI,M.等: ""RecName: Full=Sericin 1; AltName: Full=Silk gum protein; Flags: Precursor"", 《GENBANK》 * |
THITIKAN KHAMPIENG 等: ""Silk Sericin loaded Alginate Nanoparticles: Preparation and Anti-inflammatory Efficacy"", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
董志军 等: ""丝胶对糖尿病大鼠视网膜氧化应激和微炎症状态的改善作用"", 《眼科新进展》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898398A (en) * | 2021-02-04 | 2021-06-04 | 西南大学 | Truncated protein of silkworm egg collagen and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112225791B (en) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101979539B (en) | Reagents and methods for isolation of purified RNA | |
CN111658775B (en) | Role of long-chain non-coding RNA in osteogenic differentiation and adipogenic differentiation of stem cells | |
CN112225791B (en) | Sericin peptide and application thereof | |
WO2018090651A1 (en) | Method for pretreating protein in ex vivo body fluid | |
CN111454899B (en) | Application of carrageenan in inhibiting mesenchymal stem cell lipogenesis transformation | |
CN112194715B (en) | Anti-inflammatory sericin peptide and application thereof | |
CN112300258B (en) | Anti-inflammatory sericin peptide and application thereof | |
CN109735541B (en) | ACADSB gene knockout dairy cow mammary gland epithelial cell line and construction method thereof | |
JP3523597B2 (en) | Sulfated fucogalactan | |
RU2750928C1 (en) | Method for isolating exosomes from conditioned cell culture medium | |
CN112300257A (en) | Sericin with anti-inflammatory function and preparation method and application thereof | |
HUT70980A (en) | Dna isolation method | |
JP2527510B2 (en) | DNA isolation method | |
EP2492356A1 (en) | Method of detecting methylated DNA in sample | |
CN1575341A (en) | Method for preparing heparin from mast cell cultures | |
CN105648036B (en) | high-throughput screening method of L-aspartate beta-decarboxylase producing bacteria | |
CN113249375A (en) | High-throughput detection method for rapidly and efficiently enriching fecal viruses | |
CN111454880A (en) | Method for differentiating human umbilical cord mesenchymal stem cells into insulin-like masses with insulin secretion function through in-vitro induction | |
Ramya et al. | Production of extracellular protease using Bacillus species from the red soil and optimization of protease activity | |
CN113151279B (en) | hsa_circ_0001236 and application thereof | |
Guerrero-Hernández et al. | Identification and functional characterization of the siRNA pathway in Taenia crassiceps by silencing Enolase A | |
CN114107209B (en) | Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose | |
CN108504640A (en) | Steroidal compounds side chain modifier and its application | |
RU2776930C1 (en) | Method for extracting isolated cells from the jaw | |
RU2799411C1 (en) | Method of isolating total rna from human intervertebral discs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240410 Address after: 402160 No. 801 Heshun Avenue, Yongchuan District, Chongqing (1st Floor, Building 3, Zone C, Yongchuan District Big Data Industrial Park) Patentee after: Chongqing century legend technology development partnership (L.P.) Country or region after: China Address before: 400715 No. 2, natural road, Beibei District, Chongqing Patentee before: SOUTHWEST University Country or region before: China |
|
TR01 | Transfer of patent right |